GlassScriptPhysician profile
Mick S Meiselman
NPI 1801897012
$4,164.89
in general payments reported to CMS, 2019-2025
15 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $370 · 2021: $117 · 2022: $606 · 2023: $1,019 · 2024: $724 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952 · Travel and Lodging: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.41 |
| Travel and Lodging | $529.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,359.68 | 2019-2025 | Acquire, Exalt Model D, Apollo Esg System |
| Abbvie INC. | $556.15 | 2020-2025 | |
| Ovesco Endoscopy USA, INC. | $529.15 | 2023 | |
| Covidien LP | $210.55 | 2019 | |
| Janssen Biotech, INC. | $127.21 | 2019 | |
| Olympus America INC. | $87.00 | 2020 | |
| Genzyme Corporation | $68.00 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $48.26 | 2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.66 | 2020-2024 | Xifaxan |
| Ardelyx, INC. | $32.19 | 2024 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $26.59 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $25.69 | 2024 | Voquezna |
| Pfizer INC. | $23.52 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mick Meiselman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.